BC PharmaCare Newsletter

April 25, 2018 Edition 18-008
Published by the Pharmaceutical Services Division to provide information for British Columbia’s health care providers

QuickLinks
Your Voice: Patient and Caregiver Input for Drug Decisions ................................................................. 1
Is Your Pharmacy Contact Information Current? .................................................................................. 2
PRIME Project: The Future of Access to PharmaNet ................................................................. 2
Benefits ................................................................................................................................................. 3

YOUR VOICE: PATIENT AND CAREGIVER INPUT FOR DRUG DECISIONS

The feedback and experiences of patients, caregivers, and patient groups is integral to B.C.’s drug review process.

When reviewing a drug, BC PharmaCare seeks the input of people who have the condition treated by that drug, their caregivers, as well as patient groups that represent B.C. residents affected by that condition. This input is collected in online questionnaires available through the Your Voice portal. New drugs for review are posted regularly.

The Ministry depends on pharmacies and practitioners to help connect patients and their caregivers with these opportunities to provide input. If you have a patient who is currently taking one of the drugs under review or who has the condition the new drug treats, please direct them to visit www.gov.bc.ca/BCyourvoice.

BC PharmaCare is currently seeking input on the following drugs:

<table>
<thead>
<tr>
<th>DRUG NAME</th>
<th>INDICATION</th>
<th>INPUT WINDOW</th>
</tr>
</thead>
<tbody>
<tr>
<td>brodalumab (Siliq™)</td>
<td>Plaque psoriasis</td>
<td>April 25–May 23, 2018</td>
</tr>
<tr>
<td>buprenorphine hydrochloride (Probuphine™)</td>
<td>Opioid dependence</td>
<td>April 25–May 23, 2018</td>
</tr>
<tr>
<td>cladribine (Mavenclad™)</td>
<td>Relapsing-remitting multiple sclerosis</td>
<td>April 25–May 23, 2018</td>
</tr>
<tr>
<td>leterminovir (Previmis™)</td>
<td>Prophylaxis of cytomegalovirus infection</td>
<td>April 25–May 23, 2018</td>
</tr>
<tr>
<td>netupitant-palonosetron (Akynzeo™)</td>
<td>Chemotherapy-induced nausea and vomiting</td>
<td>April 25–May 23, 2018</td>
</tr>
</tbody>
</table>

The use of PharmaNet is not intended as a substitute for professional judgment. Information on PharmaNet is not exhaustive and cannot be relied upon as complete. The absence of a warning about a drug or drug combination is not an indication that the drug or drug combination is safe, appropriate or effective in any given patient. Health care professionals should confirm information obtained from PharmaNet, and ensure no additional relevant information exists, before making patient care decisions.

www.gov.bc.ca/pharmacarepharmacists | www.gov.bc.ca/pharmacareprescribers | www.gov.bc.ca/pharmacaredeviceproviders
IS YOUR PHARMACY CONTACT INFORMATION CURRENT?

PharmaCare has a designated email address on file for each pharmacy. This email contact is where PharmaCare sends important information that may affect your PharmaCare payments.

To check the email address currently on file for your pharmacy, refer to your enrollment welcome package or update forms. Alternately, you can call the PharmaNet Help Desk to confirm your pharmacy’s contact information.

To update your contact information whenever it changes (for example, when a manager or owner changes), complete Part A of the PharmaCare Provider Change form (HLTH5433).

PRIME PROJECT: THE FUTURE OF ACCESS TO PHARMANET

The Ministry of Health has launched the PharmaNet Revisions for Information Management Enhancement (PRIME) Project to update how users obtain and maintain access to PharmaNet.

PRIME will create a system for PharmaNet user management that satisfies government regulation and standards, standardizes processes across the province, positions the Ministry of Health as the approver for all PharmaNet users’ access, and ensures that all PharmaNet access is transparent and accountable.

PRIME will offer the following benefits:

- Enhance the prevention of inappropriate PharmaNet access and security breaches that put patient and practitioner information at risk.
- Protect users by providing transparent and accountable access to PharmaNet.
- Establish clearly defined criteria for access to PharmaNet.
- Establish consistent processes for all PharmaNet users and administrators across the province.
- Create a web-based, mostly automated, PRIME enrollment and information system.

The PRIME project team will engage with PharmaNet users throughout the PRIME planning, design, development and implementation phases.

The effective date of PRIME is currently under consideration and will be communicated when it is available.

More Information

More information about PRIME is available at [www.gov.bc.ca/PharmaNet/PRIME](http://www.gov.bc.ca/PharmaNet/PRIME), including a [project introduction sheet](#) and [FAQ](#).

Sign up to the [PRIME distribution list](#) to receive information about the project and progress, as well as opportunities to provide feedback.
BENEFITS

Limited Coverage Drugs

The following drugs have been added as Limited Coverage Drugs under Fair PharmaCare and Plans B, C, F, W, and, if indicated, G and P.

<table>
<thead>
<tr>
<th>COVERAGE EFFECTIVE</th>
<th>DRUG NAME</th>
<th>INDICATION</th>
<th>DIN</th>
<th>STRENGTH/FORM</th>
<th>PLAN G BENEFIT?</th>
<th>PLAN P BENEFIT?</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 24, 2018</td>
<td>secukinumab (Cosentyx®)</td>
<td>Ankylosing spondylitis and psoriatic arthritis</td>
<td>2438070</td>
<td>150 mg/mL pre-filled syringe</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Cosentyx® is also a Limited Coverage Drug for the treatment of plaque psoriasis.

<table>
<thead>
<tr>
<th>COVERAGE EFFECTIVE</th>
<th>DRUG NAME</th>
<th>INDICATION</th>
<th>DIN</th>
<th>STRENGTH/FORM</th>
<th>PLAN G BENEFIT?</th>
<th>PLAN P BENEFIT?</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 10, 2018</td>
<td>somatropin (Omnitrope®)</td>
<td>Growth hormone deficiency or chronic renal insufficiency in patients 20 years of age or younger</td>
<td>02459647</td>
<td>15 mg/1.5 mL cartridge</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Omnitrope® is also a Limited Coverage Drug available in 5 mg/1.5 mL and 10 mg/1.5 mL cartridges.

High-Cost Drugs

The following products will be added to the list of designated high-cost drugs. For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. The complete list of high-cost drugs is available online.

<table>
<thead>
<tr>
<th>DIN</th>
<th>DRUG NAME</th>
<th>Markup</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>02467542</td>
<td>sofosbuvir-velpatasvir-voxilaprevir (Vosevi™) 400-100-100 mg tablet</td>
<td>2%</td>
<td>May 25, 2018</td>
</tr>
</tbody>
</table>